Researcher Jonathan Licht at University of Florida Health, led a study and identified how a specific mutation in the NSD2 gene (E1099K) contributes to relapse in childhood acute lymphocytic leukemia (ALL). This mutation alters histone methylation patterns, making cancer cells more aggressive, resistant to cell death, and more likely to invade the brain. These findings highlight key biological pathways influenced by this mutation, paving the way for potential new treatments targeting NSD2-driven leukemia.
We are proud to partner with University Of Florida and some truly amazing and talented individuals to make these research trials possible.We invite you to explore in this page all the incredible groundbreaking research funded by the Live Like Bella Pediatric Cancer Research Initiative that will help to make pediatric cancer a treatable and curable disease.
Jonathan Licht
Identification of Therapeutic Targets and Pathways in Relapsed Childhood Acute Lymphocytic Leukemia (ALL) Associated with NSD2 Mutations.
Lamba Jatinder
Pharmacogenomics and Toxicities of Thiotepa, Busulfan, and Fludarabine in Pediatric HSCT Recipients.
Zhijian Qian
Molecular Basis and Treatment of Pediatric AML with Hyperexpression of EVI1.
Elias Sayour M.D, Ph.D
Multi-center phase I study evaluating lipid-nanoparticle vaccines against pediatric high-grade glioma.
Coy Heldermon Md, Ph.D
Novel immunologic therapy of soft tissue sarcoma.
Mingyi Xie
Target RNAs induce microRNA degradation in apoptotic T-cell acute lymphoblastic leukemia cells.
Zhijian Qian
FOXM1 as a therapeutic target for MLL-rearranged AMLs.
Raymond Mailhot
Measuring the effects of brain radiotherapy and tumor on scholastic outcome.
Jonathan Licht
NSD2 Mutation as Driver of Brain Invasion in Acute Lymphoblastic Leukemia.
Lan Hoang-Minh
Jonathan Licht
Elucidation and targeting of epigenetic changes resulting in glucocorticoid resistance in pediatric acute lymphoblastic leukemia.
Loic Deleyrolle
Co-opting TME lactate signal to benefit T cell therapy.
Paul Castillo
Unlocking CAR T cell efficacy against osteosarcoma using adjuvant RNA vaccine.
Biljana Horn
Engineered Donor Graft for Pediatric Hematopoietic Cell Transplant (HCT) Recipients with Hematologic Malignancies (HM)- Florida Pediatric Bone Marrow Transplant and Cell Therapy Consortium (FPBCC) First Prospective Multicenter Trial.
Brian Stover
Ultrasound elastogram assessment of liver fibrosis in children and adolescents/young adults (AYA) receiving chemotherapy or allogeneic bone marrow transplantation, and identification of risk factors for liver injury.
Ramzi Salloum
Point-of-care intervention to address financial toxicity in families facing pediatric cancer.
Jianping Huang
Jordan Milner
Utilization of Alpha/Beta T Cell and B Cell Depletion in Allogeneic Stem Cell Transplantation in Malignant Diseases.
Brent Reynolds
Intranasal delivery of BMP-4 using plant-derived extracellular vesicles for treatment of pediatric glioma.
Hugh Fan
Towards liquid biopsy for pediatric sarcoma.
Steven Bruner
Functional role of the srp54 gene in pediatric leukemia and bone marrow failure syndromes.
Duane Mitchell, MD, PhD
CHAMP1ON – Combinatorial Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade Phase 1 “Window of Opportunity” Trial for RecurreNt Pediatric High-Grade Glioma.
Michalina Janiszewska, PhDO
Oncofetal protein as a therapeutic target in pediatric brain tumors
🔬Explore the Research
→ Pharmacogenomics of Chemo Toxicities in Pediatric HSCT
→ EVI1-Driven Pediatric AML: Molecular Insights & Treatment
→ FOXM1 Targeting in MLL-Rearranged AML
→ Impact of Brain Radiotherapy & Tumor on School Performance
→ Combo Immunotherapy for Pediatric Brain Tumors
→ Point-of-Care Aid for Financial Strain in Pediatric Cancer